Business Context and Reporting Period
Company: Evogene Ltd. (EVGN)
Filing Type: Form 20-F Annual Report
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Evogene is a computational biology and chemistry company utilizing AI-driven platforms (primarily ChemPass AI) to discover small molecules for pharmaceutical and agricultural applications. The company operates through subsidiaries including AgPlenus (ag-chemicals), Biomica (human health), and Casterra (industrial castor seeds).
Strategic Shift: In 2025, the company streamlined operations, divesting the majority of Lavie Bio (ag-biologicals) to ICL and scaling down Biomica and Casterra activities to focus resources on the ChemPass AI platform.
Key Financial Metrics
| Metric (USD in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenues | $3,853 | $5,577 |
| Cost of Revenues | $4,094 | $2,380 |
| Gross Profit (Loss) | $(241) | $3,197 |
| Operating Loss | $(14,034) | $(18,804) |
| Net Loss (Continuing Ops) | $(13,499) | $(14,817) |
| Net Loss (Total) | $(7,827) | $(18,054) |
| Cash and Cash Equivalents (Dec 31) | $12,956 | $15,301 |
| Working Capital | $12,200 (approx) | N/A |
| Long-Term Indebtedness (Gov Grants) | $3,073 | $4,327 |
Note: The 2025 Net Loss includes a $5.67 million gain from discontinued operations (sale of Lavie Bio assets), significantly reducing the total reported loss compared to continuing operations.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 30.4% to $3.9 million, driven by the completion of the Corteva collaboration and the absence of one-time payments recognized in 2024.
- Inventory Impairment: Cost of revenues increased 70.8% due to a $2.18 million inventory impairment charge related to Casterra's decision to cease operations in Kenya.
- Operating Expense Reduction: Operating expenses decreased by approximately $8.2 million (37.3%) due to significant workforce reductions and cost-cutting measures across Biomica, Casterra, and AgPlenus.
- Discontinued Operations: The company recognized a $6.4 million gain on the sale of Lavie Bio assets and the MicroBoost AI platform to ICL, reclassifying these operations as discontinued.
- Financing Income: Financing income decreased 66.2% to $2.5 million, primarily due to the remeasurement of warrants issued in 2024.
Guidance, Outlook, and Risks
Going Concern: Management identified conditions raising substantial doubt about the company's ability to continue as a going concern for the 12-month period following the report date, citing a history of operating losses and negative cash flows. However, management believes its cost-preservation plan (headcount reductions, deferring R&D) alleviates this doubt.
Outlook:
- Strategic Focus: Continued focus on the ChemPass AI platform for small molecule discovery in pharma and agriculture.
- Collaborations: New collaborations announced in late 2025/early 2026 with Unravel Biosciences, Systasy Bioscience, and academic institutions to advance drug discovery.
- Liquidity: Sources of liquidity for 2026 include cash on hand, proceeds from the Lavie Bio sale, and potential new collaborations or financing.
Key Risks:
- Geopolitical: Ongoing conflict in Israel (Hamas, Hezbollah, Iran) poses risks to operations, employee safety, and economic stability.
- Capital Needs: The company may require substantial additional capital, potentially leading to shareholder dilution.
- Commercialization: No product candidates have completed development; revenue relies heavily on collaboration fees and milestone payments which are uncertain.
- Nasdaq Compliance: The company has faced challenges maintaining the $1.00 minimum bid price requirement, having executed a 1-for-10 reverse split in July 2024.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $13.0 million cash balance against the burn rate and the feasibility of the cost-cutting plan to sustain operations for 12 months.
- Discontinued Operations Gain: Confirm the timing of cash receipt from the $18.7 million Lavie Bio sale to ICL and the impact on current liquidity.
- Casterra Inventory: Assess the remaining value of Casterra's inventory post-impairment and the viability of the shifted focus to the Brazilian market.
- Share Price Compliance: Monitor the stock price relative to the Nasdaq $1.00 minimum bid requirement, noting the risk of delisting if compliance is not maintained post-reverse split.
- Geopolitical Exposure: Evaluate the specific impact of the ongoing regional conflict on the company's Israeli workforce and operational continuity.